Abstract
Somatostatin analogues appear to have antiproliferative effects in breast cancer by inhibiting various hormones. Several small phase 1 and 2 clinical trails have evaluated the efficacy of somatostatin analogues, but the results are varied. The purpose of this study was to use the technique of meta-analysis to determine the effect of somatostatin analogues on tumor response, toxicity, and serum hormone levels in women with metastatic breast cancer. All published and unpublished trials were reviewed. Meta-analysis was preformed by best linear unbiased estimate regression with observations weighted inversely to their variance. Significance was considered at P < .05. Fourteen studies (N = 210) were included. Positive tumor response was reported in 87 patients (41.4%). Mean duration of response was 3.9 months. Response was best when somatostatin analogues were given as first-line therapy (69.5% versus 28.5%, P < .006) and in patients with < or =2 metastases (45.0% versus 5.6%, P = .3). Mild side effects occurred in 47 of 185 patients (25.4%). Therapy was associated with a decrease in serum insulin-like growth factor (IGF-1) and an increase in growth hormone. In patients with metastatic breast cancer, treatment with somatostatin anal...Continue Reading
References
May 1, 1990·Breast Cancer Research and Treatment·D R CioccaR Sonego
Dec 20, 1990·The Journal of Steroid Biochemistry and Molecular Biology·J BonneterreA Demaille
May 1, 1989·British Journal of Cancer·J NelsonR F Murphy
Dec 1, 1989·Breast Cancer Research and Treatment·A ManniM Bartholomew
Aug 1, 1985·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·J T EmermanN Bruchovsky
Oct 1, 1982·Endocrinology·R N Mascardo, P Sherline
Jun 1, 1995·Breast Cancer Research and Treatment·A Di LeoA Bono
Nov 1, 1994·Naunyn-Schmiedeberg's Archives of Pharmacology·D HoyerC Bruns
Mar 12, 1994·Lancet·V R McCready, T F Hickish
Mar 12, 1994·Lancet·C H van EijckS W Lamberts
May 28, 1993·International Journal of Cancer. Journal International Du Cancer·A H BootsmaA de Klein
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J P PeyratA Demaille
Jan 25, 1996·The New England Journal of Medicine·S W LambertsL J Hofland
Jan 1, 1996·Investigational New Drugs·J N IngleA K Hatfield
Dec 1, 1996·Endocrinology·Y XuJ F Bruno
Mar 4, 1997·International Journal of Cancer. Journal International Du Cancer·J C SchaerJ C Reubi
Jan 1, 1997·British Journal of Cancer·A A EvansJ N Primrose
Aug 1, 1997·Nuclear Medicine Communications·J R BuscombeA J Hilson
Feb 12, 1998·British Journal of Cancer·M BontenbalJ G Klijn
Jan 19, 1999·Molecular Endocrinology·K SharmaC B Srikant
Citations
Aug 14, 2003·Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society·Anders Juul
Mar 12, 2013·International Journal of Peptides·Federica BarbieriTullio Florio
Jan 7, 2014·Cancer Metastasis Reviews·J P CastañoK Oberg
Dec 11, 2007·European Archives of Oto-rhino-laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·Luke T CondonStephen L Atkin
Apr 26, 2012·European Journal of Pharmacology·Martina MargheriLucia Formigli
Mar 1, 2008·Molecular and Cellular Endocrinology·Heather L WattUjendra Kumar
Mar 23, 2011·Biochimica Et Biophysica Acta·Geetanjali KharmateUjendra Kumar
Dec 6, 2018·International Journal of Molecular Sciences·Rosamaria LappanoMarcello Maggiolini
Feb 27, 2003·The Oncologist·Rita NahtaFrancisco J Esteva
Feb 16, 2021·Frontiers in Endocrinology·Marco GalloAnnamaria Anita Livia Colao